PCI Biotech (Norway) Today
| PCIB Stock | NOK 1.64 0.20 10.87% |
Performance0 of 100
| Odds Of DistressLess than 10
|
PCI Biotech is selling for 1.64 as of the 28th of November 2024. This is a 10.87% down since the beginning of the trading day. The stock's lowest day price was 1.45. PCI Biotech has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for PCI Biotech Holding are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization technology platform. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Oslo, Norway. The company has 37.33 M outstanding shares. More on PCI Biotech Holding
Moving against PCI Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
PCI Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. PCI Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding PCI Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO CFO | Ronny Skuggedal |
| Thematic Idea | IT (View all Themes) |
| Business Concentration | IT, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) |
PCI Biotech Holding (PCIB) is traded on Oslo Stock Exchange in Norway and employs 14 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 81.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate PCI Biotech's market, we take the total number of its shares issued and multiply it by PCI Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. PCI Biotech Holding operates under Biotechnology sector and is part of Health Care industry. The entity has 37.33 M outstanding shares.
PCI Biotech Holding has accumulated about 116.12 M in cash with (68.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.83, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check PCI Biotech Probability Of Bankruptcy
Ownership AllocationPCI Biotech owns a total of 37.33 Million outstanding shares. PCI Biotech Holding has substantial amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check PCI Ownership Details
PCI Biotech Holding Risk Profiles
Although PCI Biotech's alpha and beta are two of the key measurements used to evaluate PCI Biotech's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.82 | |||
| Semi Deviation | 4.29 | |||
| Standard Deviation | 6.9 | |||
| Variance | 47.66 |
PCI Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in PCI Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Other Information on Investing in PCI Stock
PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.